BioCryst Pharma (BCRX) Misses Q1 EPS by 303c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.47 -0.59%
Revenue Growth %: +3.9%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +3.9%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($2.98), $3.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $156.41 million versus the consensus estimate of $151.66 million.
GUIDANCE:
BioCryst Pharma sees FY2026 revenue of $635-660 million, versus the consensus of $650.2 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
